Dr. O'Regan on Future of Chemotherapy in Breast Cancer

Video

In Partnership With:

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.

Chemotherapy is likely to stay in the treatment armamentarium in breast cancer, at least in the foreseeable future, O’Regan says. This is particularly the case in HER2-positive disease and in triple negative breast cancer, where chemotherapy plays a crucial role in the treatment sequence. However, the field of estrogen receptor (ER)—positive breast cancer seems to be moving away from chemotherapy.

Even if a patient with ER-positive disease has positive lymph nodes, they still might not benefit from chemotherapy if they have a low recurrence score. Interestingly, O’Regan adds, even patients with ER-positive disease who are at a high risk of recurrence typically do not benefit much from chemotherapy, although they are treated with it because there are no other options. Chemotherapy with CDK4/6 inhibitors might be an answer, O’Regan concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD